ClinicalTrials.gg
CompletedNCT00711269Updated Apr 12, 2022Results posted

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

A Phase 3 interventional study of SM-13496 (lurasidone HCl) and SM-13496 (lurasidone HCl) in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.

Enrollment
7th of 39
460 · median 149
Started
2008
with 8 others
Phase 3
18 of 39
none open now
Registered
8th of 39
by date
Lead sponsor
3 of 39
Sumitomo Pharma Co., Ltd.

Among the 39 studies testing lurasidone in Schizophrenia, this one is the 7th largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing lurasidone in Schizophrenia as a file.
02

Study summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patient meets criteria for schizophrenia.
  • Patient is 18 or older but younger than 75 years of age on the day of signing .
  • Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.

Main Exclusion Criteria:

  • Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
  • Patient has Parkinson's disease.
  • Patient has a history or complication of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    SM-13496 (lurasidone HCl) 40mg

    SM-13496 40 mg was administered orally once daily.

    Drug: SM-13496 (lurasidone HCl)

  • Experimental
    SM-13496 (lurasidone HCl) 80mg

    SM-13496 80mg was administered orally once daily.

    Drug: SM-13496 (lurasidone HCl)

  • Placebo comparator
    Placebo

    Placebo was administered orally twice daily.

    Drug: Placebo

  • Active comparator
    Risperidone

    Risperidone was administered orally twice daily.

    Drug: Risperidone

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)

    The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

    Time frame: Baseline and Week 6 [Last Observation Carried Forward (LOCF)]

Secondary outcomes

  1. Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)

    The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: Baseline and Week 6 (LOCF)

  2. Change From Baseline in the PANSS Negative Subscales at Week 6

    The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

    Time frame: Baseline and Week 6 (LOCF)

  3. Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)

    The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

    Time frame: Baseline and Week 6 (LOCF)

  4. Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)

    Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a study participant who was taking a medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.

    Time frame: From Baseline to up to 8 weeks

  5. Proportion of Participants With TEAEs Leading to Discontinuation

    Time frame: From Baseline to up to 8 weeks

  6. Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

    Proportion of participants with treatment-emergent adverse events. An adverse event was considered serious if it met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Was considered to be an important medical event.

    Time frame: From Baseline to up to 8 weeks

07

Results

Posted Oct 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Started13113113365
Completed87838351
Not completed44485014

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)

The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Time frame:
Baseline and Week 6 [Last Observation Carried Forward (LOCF)]
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)
units on a scaleSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)-6.1 ± 1.75-4.3 ± 1.72-2.5 ± 1.72-7.1 ± 2.44
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40-mg Group vs Placebo Group · ANOVA · p = 0.149 · Ls mean difference: -3.5 · 95% CI -8.4 to 1.3\[Not specified\]
  • SM-13496 (Lurasidone HCl) 80-mg Group vs Placebo Group · ANOVA · p = 0.462 · Ls mean difference: -1.8 · 95% CI -6.6 to 3.0
  • Placebo Group vs Risperidone Group · ANOVA · p = 0.122 · Ls mean difference: -4.6 · 95% CI -10.5 to 1.2
  • SM-13496 (Lurasidone HCl) 40-mg Group vs SM-13496 (Lurasidone HCl) 80-mg Group vs Placebo Group · Maximum Contrast Method · p = 0.235 (Contrast Factors (Placebo, SM-13496 40-mg, SM-13496 80-mg): (-1, 0, 1) Adjusted P Value: 0.298)Contrast (Placebo, SM-13496 40-mg, SM-13496 80-mg):(-2, 1, 1) Raw P Value: 0.108 Adjusted P Value: 0.145
SecondaryChange From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)

The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
Baseline and Week 6 (LOCF)
Reported as:
Least squares mean · units on a scale
Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)
units on a scaleSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)-2.0 ± 0.55-1.4 ± 0.54-0.6 ± 0.54-2.9 ± 0.77
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40-mg Group vs Placebo Group · ANOVA · p = 0.069 · Ls mean difference: -1.4 · 95% CI -2.9 to 0.1
  • SM-13496 (Lurasidone HCl) 80-mg Group vs Placebo Group · ANOVA · p = 0.287 · Ls mean difference: -0.8 · 95% CI -2.3 to 0.7
  • Placebo Group vs Risperidone Group · ANOVA · p = 0.016 · Ls mean difference: -2.3 · 95% CI -4.1 to -0.4
SecondaryChange From Baseline in the PANSS Negative Subscales at Week 6

The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.

Time frame:
Baseline and Week 6 (LOCF)
Reported as:
Least squares mean · units on a scale
Change From Baseline in the PANSS Negative Subscales at Week 6
units on a scaleSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Change From Baseline in the PANSS Negative Subscales at Week 6-1.6 ± 0.47-1.7 ± 0.46-0.9 ± 0.46-1.7 ± 0.65
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40-mg Group vs Placebo Group · ANOVA · p = 0.289 · Ls mean difference: -0.7 · 95% CI -2.0 to 0.6
  • SM-13496 (Lurasidone HCl) 80-mg Group vs Placebo Group · ANOVA · p = 0.256 · Ls mean difference: -0.7 · 95% CI -2.0 to 0.5
  • Placebo Group vs Risperidone Group · ANOVA · p = 0.352 · Ls mean difference: -0.7 · 95% CI -2.3 to 0.8
SecondaryChange From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)

The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.

Time frame:
Baseline and Week 6 (LOCF)
Reported as:
Least squares mean · units on a scale
Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)
units on a scaleSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)-2.4 ± 0.90-1.2 ± 0.88-1.0 ± 0.88-2.6 ± 1.25
Statistical analysis
  • SM-13496 (Lurasidone HCl) 40-mg Group vs Placebo Group · ANOVA · p = 0.251 · Ls mean difference: -1.4 · 95% CI -3.9 to 1.0
  • SM-13496 (Lurasidone HCl) 80-mg Group vs Placebo Group · ANOVA · p = 0.847 · Ls mean difference: -0.2 · 95% CI -2.7 to 2.2
  • Placebo Group vs Risperidone Group · ANOVA · p = 0.292 · Ls mean difference: -1.6 · 95% CI -4.6 to 1.4
SecondaryProportion of Participants With Treatment-emergent Adverse Events (TEAEs)

Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a study participant who was taking a medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.

Time frame:
From Baseline to up to 8 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)10510310153
SecondaryProportion of Participants With TEAEs Leading to Discontinuation
Time frame:
From Baseline to up to 8 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With TEAEs Leading to Discontinuation
ParticipantsSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Proportion of Participants With TEAEs Leading to Discontinuation1818277
SecondaryProportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)

Proportion of participants with treatment-emergent adverse events. An adverse event was considered serious if it met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Was considered to be an important medical event.

Time frame:
From Baseline to up to 8 weeks
Reported as:
Count of participants · Participants
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)87102

Adverse events

Collected over From Baseline to up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SM-13496 (Lurasidone HCl) 40-mg Group0/127 (0%)8/127 (6.3%)97/127 (76.4%)
SM-13496 (Lurasidone HCl) 80-mg Group1/131 (0.8%)7/131 (5.3%)124/131 (94.7%)
Placebo Group0/132 (0%)10/132 (7.6%)91/132 (68.9%)
Risperidone Group0/65 (0%)2/65 (3.1%)51/65 (78.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
SchizophreniaPsychiatric disorders3/1272/1316/1320/65
Psychotic disorderPsychiatric disorders3/1271/1312/1321/65
Neuroleptic malignant syndromeNervous system disorders0/1270/1310/1321/65
CellulitisInfections and infestations1/1270/1311/1320/65
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/1270/1310/1320/65
Abdominal pain upperGastrointestinal disorders0/1271/1310/1320/65
NauseaGastrointestinal disorders0/1271/1310/1320/65
VomitingGastrointestinal disorders0/1271/1310/1320/65
Sudden deathGeneral disorders0/1271/1310/1320/65
Skin lacerationInjury, poisoning and procedural complications0/1271/1310/1320/65
Most frequent other events
Showing 10 of 217
Most frequent other events
EventSM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone Group
SchizophreniaPsychiatric disorders15/12725/13125/13210/65
InsomniaPsychiatric disorders18/12725/13119/1324/65
ConstipationGastrointestinal disorders10/12711/13114/13212/65
NasopharyngitisInfections and infestations13/12713/13113/1329/65
AkathisiaNervous system disorders11/12715/1316/1329/65
VomitingGastrointestinal disorders11/12713/13111/1324/65
HeadacheNervous system disorders8/12711/13110/1323/65
Blood prolactin increasedInvestigations1/1270/1310/1325/65
TremorNervous system disorders3/12710/1318/1325/65
NauseaGastrointestinal disorders9/1274/1316/1322/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)SM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone GroupTotal
Mean45.6 ± 14.4845.7 ± 13.5146.0 ± 12.8544.8 ± 12.5945.6 ± 13.44
Sex: Female, Male
Sex: Female, Male(Participants)SM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone GroupTotal
Female50475729183
Male75827235264
Region of Enrollment
Region of Enrollment(participants)SM-13496 (Lurasidone HCl) 40-mg GroupSM-13496 (Lurasidone HCl) 80-mg GroupPlacebo GroupRisperidone GroupTotal
Japan63646133221
Taiwan34373816125
Korea, Republic of28283015101
08

Study locations

3 sites
  • Japan: 67 sites
    Tokyo, Etc., Japan
  • Korea: 14 sites
    Seoul, Etc., Korea, Republic of
  • Taiwan: 11 sites
    Taipei, Etc., Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2008 to primary completion in Apr 2010, 22 months.

Results were first posted in Oct 2018, 8 years 5 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 22 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2008
First posted
Jul 8, 2008
StartActual
Jun 27, 2008
Primary completionActual
Apr 27, 2010
CompletionActual
Apr 27, 2010
Results first posted
Oct 19, 2018
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00711269
Responsible party
Sponsor
First posted
Jul 8, 2008
Start date
Jun 27, 2008
Primary completion
Apr 27, 2010
Completion
Apr 27, 2010
Results posted
Oct 19, 2018
Last update
Apr 12, 2022

Study contacts

Drug Development Division
study director · Sumitomo Pharma Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion